257 related articles for article (PubMed ID: 23604106)
1. Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges.
Srivastava PK; Duan F
Cancer Immunol Immunother; 2013 May; 62(5):967-74. PubMed ID: 23604106
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
3. Computational Methods for Identification of T Cell Neoepitopes in Tumors.
Jurtz VI; Olsen LR
Methods Mol Biol; 2019; 1878():157-172. PubMed ID: 30378075
[TBL] [Abstract][Full Text] [Related]
4. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.
Srivastava N; Srivastava PK
PLoS One; 2009 Jul; 4(7):e6094. PubMed ID: 19593447
[TBL] [Abstract][Full Text] [Related]
5. Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
Mukherjee S
Cancer Biother Radiopharm; 2019 Oct; 34(8):487-497. PubMed ID: 31314580
[TBL] [Abstract][Full Text] [Related]
6. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics for cancer immunology and immunotherapy.
Charoentong P; Angelova M; Efremova M; Gallasch R; Hackl H; Galon J; Trajanoski Z
Cancer Immunol Immunother; 2012 Nov; 61(11):1885-903. PubMed ID: 22986455
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines.
Vormehr M; Türeci Ö; Sahin U
Annu Rev Med; 2019 Jan; 70():395-407. PubMed ID: 30691374
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics for cancer immunotherapy target discovery.
Olsen LR; Campos B; Barnkob MS; Winther O; Brusic V; Andersen MH
Cancer Immunol Immunother; 2014 Dec; 63(12):1235-49. PubMed ID: 25344903
[TBL] [Abstract][Full Text] [Related]
10. 8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.
Boudreau JE; Wouters MC; Krawczyk CM
Cancer Immunol Immunother; 2016 Feb; 65(2):235-41. PubMed ID: 26759005
[No Abstract] [Full Text] [Related]
11. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
12. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
13. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
Martin SD; Coukos G; Holt RA; Nelson BH
Ann Oncol; 2015 Dec; 26(12):2367-74. PubMed ID: 26371284
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics for Cancer Immunotherapy.
Holtsträter C; Schrörs B; Bukur T; Löwer M
Methods Mol Biol; 2020; 2120():1-9. PubMed ID: 32124308
[TBL] [Abstract][Full Text] [Related]
15. RNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy.
Lau D; Bobe AM; Khan AA
Trends Cancer; 2019 Mar; 5(3):149-156. PubMed ID: 30898262
[TBL] [Abstract][Full Text] [Related]
16. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
[TBL] [Abstract][Full Text] [Related]
17. It's a long way to the top (if you want to personalize immunotherapy).
Haebe S; Weigert O
J Immunother Cancer; 2017; 5():6. PubMed ID: 28116089
[TBL] [Abstract][Full Text] [Related]
18. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
19. Novel tools to assist neoepitope targeting in personalized cancer immunotherapy.
Saini SK; Rekers N; Hadrup SR
Ann Oncol; 2017 Dec; 28(suppl_12):xii3-xii10. PubMed ID: 29092006
[TBL] [Abstract][Full Text] [Related]
20. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
Sensi M; Anichini A
Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
